DMAC
DiaMedica Reports Phase 2 Preeclampsia Results & Q2 2026 Financials
Company announced positive Phase 2 top-line results for DM199 in preeclampsia and completed enrollment for its fetal growth restriction trial, projecting cash runway through 2027.
Earnings|Guidance|M&A|Buyback|Dividend|Leadership|Restructuring|Regulatory|Legal|Cyber|Offering|Bankruptcy|Other
Aug 10, 2026
sentiment +0.20
SEC filing ↗
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.